-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RdTJpVv0hB7cz2YXHrzBHlyvR3t7mvexmDfrAvl3xEx79/I88zYCyxeDgIqZZ9A5
 uRMZubdVB2ytrXvkGcwbkw==

<SEC-DOCUMENT>0001275287-05-000671.txt : 20050223
<SEC-HEADER>0001275287-05-000671.hdr.sgml : 20050223
<ACCEPTANCE-DATETIME>20050223090110
ACCESSION NUMBER:		0001275287-05-000671
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20050222
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050223
DATE AS OF CHANGE:		20050223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KEWAUNEE SCIENTIFIC CORP /DE/
		CENTRAL INDEX KEY:			0000055529
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY APPARATUS & FURNITURE [3821]
		IRS NUMBER:				380715562
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-05286
		FILM NUMBER:		05632905

	BUSINESS ADDRESS:	
		STREET 1:		2700 W FRONT ST
		CITY:			STATESVILLE
		STATE:			NC
		ZIP:			28677
		BUSINESS PHONE:		7048737202

	MAIL ADDRESS:	
		STREET 1:		P O BOX 1842
		CITY:			STATESVILLE
		STATE:			NC
		ZIP:			28687-1842

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEWAUNEE SCIENTIFIC EQUIPMENT CORP /DE/
		DATE OF NAME CHANGE:	19861216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEWAUNEE MANUFACTURING CO
		DATE OF NAME CHANGE:	19680108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ks2107.txt
<TEXT>
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported) February 22, 2005

                         Kewaunee Scientific Corporation
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

                Delaware                  0-5286           38-0715562
      ----------------------------     ------------    -------------------
      (State or other jurisdiction     (Commission      (I.R.S. Employer
            of incorporation)          File Number)    Identification No.)

                2700 West Front Street
             Statesville, North Carolina                      28677
       ----------------------------------------             ----------
       (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code 704-873-7202


         --------------------------------------------------------------
         (Former name or former address, if changed since last report.)

                                       N/A

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities
    Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
    Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13a-4(c))

================================================================================

<PAGE>

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITIONS

On February 22, 2005, Kewaunee Scientific Corporation issued a press release
announcing its financial results for the third quarter ended January 31, 2005. A
copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(C)      EXHIBITS:

EXHIBIT NO.
    99.1         Press Release of Kewaunee Scientific Corporation dated
                 February 22, 2005

In accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), or otherwise subject to the liabilities of that section,
and shall not be incorporated by reference into any registration statement or
other document filed under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such filing.

<PAGE>

                                    SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           (Registrant)
                                           Kewaunee Scientific Corporation

Date:  February 22, 2005                   /s/ D. MICHAEL PARKER
                                           -------------------------------------
                                           Senior Senior Vice President, Finance
                                           Chief Financial Officer
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ks2107ex991.txt
<TEXT>
                                                                    Exhibit 99.1

   KEWAUNEE SCIENTIFIC ANNOUNCES THIRD QUARTER RESULTS AND QUARTERLY DIVIDEND

    STATESVILLE, N.C., Feb. 22 /PRNewswire-FirstCall/ -- Kewaunee Scientific
Corporation (Nasdaq: KEQU) today reported results for its third quarter ended
January 31, 2005 and announced its regular quarterly dividend.

    Sales for the quarter were $15,623,000, a decrease of 27% from sales of
$21,454,000 in the same period last year. A net loss of $742,000, or $0.30 per
diluted share, was reported for the quarter. This compares to net earnings of
$291,000, or $0.12 per diluted share, in the same period last year.

    Sales for the quarter were adversely affected by the continuing soft
marketplace for laboratory furniture, although the marketplace appeared to show
improvement late in the quarter. Spending for new research projects by
pharmaceutical companies continued to be below levels of recent years.
Additionally, the number of projects generally available in the marketplace was
reduced, or construction has been delayed, by the significant increases in the
cost of construction materials over the past year. Funding available for
education construction projects also continued to be affected by reduced state
spending budgets.

    Order activity improved over the two previous quarters. The order backlog
increased to $41.7 million at January 31, 2005. The order backlog was $38.6
million at October 31, 2004 and $39.6 million at July 31, 2004.

    Earnings for the quarter were adversely affected by low sales volumes,
extraordinarily higher costs for certain raw materials, particularly steel and
epoxy resin, reserves established for several project disputes, and cost
overruns on several completed projects. The impact of these items was partially
offset by reduced expenses resulting from the workforce reductions announced
last quarter and aggressive cost reduction activities.

    "The business environment remained difficult during the quarter," said
William A. Shumaker, President and Chief Executive Officer of Kewaunee.
"However, as we anticipated, we have begun to see increased activity in the
marketplace since the Presidential election in November. With this improvement
expected to continue and our increased order backlog, we expect substantially
improved sales volume in the fourth quarter compared to the third quarter. In
view of this increased sales volume and with the number of unusual expenses that
affected our third quarter believed to be behind us, we expect a profitable
fourth quarter.

    "Our balance sheet remains strong," Mr. Shumaker continued. "Total debt was
$4.7 million at January 31, 2005, down from $7.6 million at October 31, 2004,
while cash on hand increased to $1.1 million. Operations provided cash of $3.8
million during the quarter. Profits of our technical furniture business continue
to improve over the prior year as this market strengthens. Our subsidiaries in
Asia serving the rapidly-expanding Asian laboratory research market also
continue to grow and contribute nicely, though modestly, to our profits."

<PAGE>

    Sales for the nine months ended January 31, 2005 were $54,276,000, a
decrease of 23% from sales of $70,051,000 in the comparable period last year. A
net loss of $441,000, or $0.18 per diluted share, was reported for the nine
months. This compares to net earnings of $1,170,000, or $.47 per diluted share,
in the comparable period last year.

    The Company also announced today that its Board of Directors approved a cash
dividend of seven cents per outstanding share to stockholders of record at the
close of business on March 4, 2005, payable on March 18, 2005.

    Kewaunee Scientific Corporation is a recognized leader in the design,
manufacture, and installation of scientific and technical furniture. The
Company's corporate headquarters and manufacturing facilities are located in
Statesville, North Carolina. Kewaunee Scientific's website is located at
http://www.kewaunee.com .

    Certain statements in this release constitute "forward-looking" statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that could significantly impact results or achievements expressed
or implied by such forward-looking statements. These factors include, but are
not limited to, economic, competitive, governmental, and technological factors
affecting the Company's operations, markets, products, services, and prices.

<PAGE>

                 Condensed Consolidated Statements of Operations
                                   (unaudited)
                      (in thousands, except per share data)

<TABLE>
<CAPTION>
                                                   3 Months Ended                9 Months Ended
                                                     January 31                    January 31
                                             ---------------------------   ---------------------------
                                                 2005           2004           2005           2004
                                             ------------   ------------   ------------   ------------
<S>                                          <C>            <C>            <C>            <C>
Net sales                                    $     15,623   $     21,454   $     54,276   $     70,051
Cost of products sold                              13,586         17,736         45,310         58,626
Gross profit                                        2,037          3,718          8,966         11,425

Operating expenses                                  3,030          3,206          9,336          9,528

Operating earnings (loss)                            (993)           512           (370)         1,897

Other expense                                        (131)           (57)          (298)           (69)

Earnings (loss) before income taxes                (1,124)           455           (668)         1,828

Income tax expense (benefit)                         (382)           164           (227)           658

Net earnings (loss)                          $       (742)  $        291   $       (441)  $      1,170

Net earnings (loss) per share
   Basic                                     $      (0.30)  $       0.12   $      (0.18)  $       0.47
   Diluted                                   $      (0.30)  $       0.12   $      (0.18)  $       0.47
Weighted average number of common
 shares outstanding (in thousands)
   Basic                                            2,492          2,486          2,491          2,485
   Diluted                                          2,493          2,499          2,495          2,493
</TABLE>

<PAGE>

                      Condensed Consolidated Balance Sheets
                                 (in thousands)

                                              January 31      April 30
                                                 2005           2004
                                             ------------   ------------
                                              (unaudited)
Assets
Cash and cash equivalents                    $      1,128   $      1,167
Receivables, less allowances                       18,756         24,987
Inventories                                         3,953          4,285
Prepaid expenses and other current assets           1,291          1,097
   Total current assets                            25,128         31,536
Net property, plant and equipment                  10,729         11,362
Other assets                                        6,513          7,563
Total Assets                                 $     42,370   $     50,461

Liabilities and Stockholders' Equity

Short-term borrowings                        $      3,263   $      6,996
Current portion of long-term debt                   1,169          1,118
Accounts payable                                    5,189          6,924
Other current liabilities                           2,535          3,881
   Total current liabilities                       12,156         18,919
Long-term debt                                        257            931
Other non-current liabilities                       4,153          3,820
Total stockholders' equity                         25,804         26,791
Total Liabilities and Stockholders' Equity   $     42,370   $     50,461

Contact:  D. Michael Parker
          704/871-3290

SOURCE  Kewaunee Scientific Corporation
    -0-                             02/22/2005
    /CONTACT:  D. Michael Parker of Kewaunee Scientific Corporation,
+1-704-871-3290/
    /Web site:  http://www.kewaunee.com /
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
